InspireMD (NSPR) reported third-quarter 2026 revenue of $2.242 million, down 11.1% from $2.523 million a year earlier. The company posted a net loss of $9.762 million, or $0.12 per basic and diluted share, compared with a $12.708 million loss, or $0.17 per share, in the prior-year quarter.
The company also received FDA approval for CGuard Prime for transcarotid arterial revascularization procedures and expects to begin U.S. sales in the fourth quarter of 2026.
- International revenue rose 9.1% to $2.210 million, while U.S. revenue fell to $32,000 from $497,000.
- Gross profit was $240,000, compared with $864,000 a year earlier.
- Operating expenses decreased 26.7% to $10.193 million and included $1.074 million of restructuring costs.
- Cash, cash equivalents and marketable securities totaled $19.246 million as of September 30, 2026.
- For the first nine months of 2026, revenue increased 27.1% to $7.411 million.
$NSPR Insider Trading Activity
$NSPR insiders have traded $NSPR stock on the open market 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $NSPR stock by insiders over the last 6 months:
- PAUL STUKA has made 2 purchases buying 25,000 shares for an estimated $23,250 and 0 sales.
- SHANE THOMAS GLEASON (Chief Commercial Officer) sold 22,778 shares for an estimated $23,005
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NSPR Hedge Fund Activity
We have seen 12 institutional investors add shares of $NSPR stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VELAN CAPITAL INVESTMENT MANAGEMENT LP removed 1,951,514 shares (-92.9%) from their portfolio in Q2 2026, for an estimated $1,366,254
- ABERDEEN GROUP PLC added 525,000 shares (+16.5%) to their portfolio in Q2 2026, for an estimated $367,552
- UBS GROUP AG added 128,339 shares (+2415.1%) to their portfolio in Q3 2026, for an estimated $85,704
- ESSEX INVESTMENT MANAGEMENT CO LLC removed 114,085 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $79,870
- SCHONFELD STRATEGIC ADVISORS LLC added 99,275 shares (+inf%) to their portfolio in Q2 2026, for an estimated $69,502
- MILLENNIUM MANAGEMENT LLC removed 74,746 shares (-66.5%) from their portfolio in Q2 2026, for an estimated $52,329
- HRT FINANCIAL LP added 59,754 shares (+inf%) to their portfolio in Q2 2026, for an estimated $41,833
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
